(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Nikola, Canopy Growth, and Artelo Biosciences.

The three biggest losers today are Addex Therapeutics Ltd, Wheeler Real Estate Investment Trust, and Senmiao Technology Limited.

Winners today

1. Nikola (NKLA) – 34.33%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola jumping 34.33% to $1.17 on Thursday while NASDAQ rose 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -132.55%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.3%, now sitting on 56.84M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Nikola’s EBITDA is 22.24.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 46.4% and 67.6%, respectively.

More news about Nikola.

2. Canopy Growth (CGC) – 14.65%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 14.65% to $1.33 on Thursday while NASDAQ jumped 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-3.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 71.4% and 80%, respectively.

Yearly Top and Bottom Value

Canopy Growth’s stock is valued at $1.33 at 17:32 EST, way under its 52-week high of $4.77 and way higher than its 52-week low of $0.35.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 405.71M for the twelve trailing months.

Volume

Today’s last reported volume for Canopy Growth is 109860000 which is 134.68% above its average volume of 46811400.

Previous days news about Canopy Growth

• : canopy growth stock continues slide after big runup. According to MarketWatch on Wednesday, 13 September, "In regular trading on Tuesday, Canopy Growth stock fell nearly 21% after big runups in recent sessions after the U.S. Drug Enforcement Agency said on Aug. 30 it would review the Schedule I classification of cannabis. ", "Even with the loss, Canopy Growth stock is still up about 67% in the past five days."

More news about Canopy Growth.

3. Artelo Biosciences (ARTLW) – 9.82%

NASDAQ ended the session with Artelo Biosciences rising 9.82% to $0.04 on Thursday while NASDAQ rose 0.81% to $13,926.05.

More news about Artelo Biosciences.

4. SmileDirectClub (SDC) – 8.78%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub jumping 8.78% to $0.42 on Thursday, after five successive sessions in a row of losses. NASDAQ rose 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.

More news about SmileDirectClub.

5. Novavax (NVAX) – 8.32%

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax rising 8.32% to $7.97 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Yearly Top and Bottom Value

Novavax’s stock is valued at $7.97 at 17:32 EST, way under its 52-week high of $33.37 and way higher than its 52-week low of $5.61.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Novavax’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Novavax’s EBITDA is 0.37.

Revenue Growth

Year-on-year quarterly revenue growth grew by 128.3%, now sitting on 1.6B for the twelve trailing months.

More news about Novavax.

6. DISH Network (DISH) – 8.31%

DISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. The company also provides access to movies and television shows through TV or Internet-connected devices; and dishanywhere.com and mobile applications on Internet-connected devices to view authorized content, search program listings, and remotely control certain features of their DVRs. In addition, it offers Sling TV services, including Sling domestic, Sling International, Sling Latino, Sling Orange, and Sling Blue services that require an internet connection and are available on streaming-capable devices, such as streaming media devices, TVs, tablets, computers, game consoles, and phones, as well as market SLING TV services to consumers who do not subscribe to traditional satellite and cable pay-TV services. Further, the company provides wireless subscribers consumer plans with no annual service contracts, as well as monthly service plans, including high-speed data and unlimited talk and text. The company offers receiver systems and programming through direct sales channels, as well as independent third parties, such as small retailers, direct marketing groups, local and regional consumer electronics stores, retailers, and telecommunications companies. DISH Network Corporation was founded in 1980 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with DISH Network jumping 8.31% to $6.78 on Thursday while NASDAQ jumped 0.81% to $13,926.05.

Earnings Per Share

As for profitability, DISH Network has a trailing twelve months EPS of $2.77.

PE Ratio

DISH Network has a trailing twelve months price to earnings ratio of 2.45. Meaning, the purchaser of the share is investing $2.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.31%.

Sales Growth

DISH Network’s sales growth is negative 8.3% for the present quarter and negative 5.9% for the next.

Volatility

DISH Network’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.69%, a negative 1.29%, and a positive 2.98%.

DISH Network’s highest amplitude of average volatility was 2.53% (last week), 2.43% (last month), and 2.98% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

DISH Network’s EBITDA is 1.62.

Volume

Today’s last reported volume for DISH Network is 6010660 which is 46.85% below its average volume of 11310300.

More news about DISH Network.

7. Riot Blockchain (RIOT) – 8.12%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 8.12% to $11.11 on Thursday, following the last session’s downward trend. NASDAQ rose 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.82%.

Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $11.11 at 17:32 EST, way below its 52-week high of $20.65 and way higher than its 52-week low of $3.25.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 16.7% and positive 71.1% for the next.

More news about Riot Blockchain.

8. Altimmune (ALT) – 7.9%

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Altimmune rising 7.9% to $2.88 on Thursday while NASDAQ jumped 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Altimmune has a trailing twelve months EPS of $-1.75.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.89%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 14.6% and a drop 4.7% for the next.

More news about Altimmune.

9. AlloVir (ALVR) – 7.89%

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

NASDAQ ended the session with AlloVir jumping 7.89% to $2.66 on Thursday while NASDAQ rose 0.81% to $13,926.05.

Earnings Per Share

As for profitability, AlloVir has a trailing twelve months EPS of $-1.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -86.07%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 16% and a drop 8.1% for the next.

More news about AlloVir.

10. Aeglea BioTherapeutics (AGLE) – 7.87%

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

NASDAQ ended the session with Aeglea BioTherapeutics rising 7.87% to $14.94 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Aeglea BioTherapeutics has a trailing twelve months EPS of $-70.24.

Volume

Today’s last reported volume for Aeglea BioTherapeutics is 45141 which is 83.12% below its average volume of 267467.

More news about Aeglea BioTherapeutics.

Losers Today

1. Addex Therapeutics Ltd (ADXN) – -16.25%

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and research collaboration agreement with Indivior PLC. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

NASDAQ ended the session with Addex Therapeutics Ltd dropping 16.25% to $0.44 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Addex Therapeutics Ltd has a trailing twelve months EPS of $-1.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -197.74%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Addex Therapeutics Ltd’s EBITDA is 0.09.

Yearly Top and Bottom Value

Addex Therapeutics Ltd’s stock is valued at $0.44 at 17:32 EST, way under its 52-week high of $2.28 and higher than its 52-week low of $0.42.

More news about Addex Therapeutics Ltd.

2. Wheeler Real Estate Investment Trust (WHLRP) – -15%

Headquartered in Virginia Beach, VA, Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR ) is a fully integrated, self-managed commercial real estate investment company focused on owning and operating income-producing retail properties with a primary focus on grocery-anchored centers.

NASDAQ ended the session with Wheeler Real Estate Investment Trust sliding 15% to $1.36 on Thursday while NASDAQ rose 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Wheeler Real Estate Investment Trust has a trailing twelve months EPS of $-1.868.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.59%.

Volume

Today’s last reported volume for Wheeler Real Estate Investment Trust is 8561 which is 31.84% above its average volume of 6493.

Moving Average

Wheeler Real Estate Investment Trust’s value is way below its 50-day moving average of $1.73 and way under its 200-day moving average of $1.69.

More news about Wheeler Real Estate Investment Trust.

3. Senmiao Technology Limited (AIHS) – -10.86%

Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. Its services include the facilitation of automobile transaction and financing, connecting ride-hailing drivers to financial institutions to buy, or get financing on the purchase of, cars to be used to provide ride-hailing services. The company is also involved in the sale of automobiles; and provision of auto finance services. Senmiao Technology has strategic cooperation with Gaode Map for utilization in ride sharing initiatives. Senmiao Technology Limited was incorporated in 2017 and is based in Chengdu, the People's Republic of China.

NASDAQ ended the session with Senmiao Technology Limited falling 10.86% to $0.45 on Thursday, after two successive sessions in a row of losses. NASDAQ rose 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Senmiao Technology Limited has a trailing twelve months EPS of $-0.52.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.54%.

Volume

Today’s last reported volume for Senmiao Technology Limited is 27430 which is 55.74% below its average volume of 61982.

Moving Average

Senmiao Technology Limited’s value is way below its 50-day moving average of $0.53 and way below its 200-day moving average of $0.78.

Revenue Growth

Year-on-year quarterly revenue growth declined by 10.6%, now sitting on 7.84M for the twelve trailing months.

More news about Senmiao Technology Limited.

4. Arcutis Biotherapeutics (ARQT) – -9.6%

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

NASDAQ ended the session with Arcutis Biotherapeutics falling 9.6% to $6.78 on Thursday, following the last session’s downward trend. NASDAQ rose 0.81% to $13,926.05, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Arcutis Biotherapeutics has a trailing twelve months EPS of $-6.11.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -239.82%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 45.5% and 0.8%, respectively.

Yearly Top and Bottom Value

Arcutis Biotherapeutics’s stock is valued at $6.78 at 17:32 EST, way below its 52-week high of $20.64 and higher than its 52-week low of $6.39.

More news about Arcutis Biotherapeutics.

5. AirNet Technology (ANTE) – -9.21%

AirNet Technology Inc. operates out-of-home advertising platforms in the People's Republic of China. The company provides advertising time slots in the form of digital TV screens on airplanes; and media contents display in air travel; and gas station media network. It also displays non-advertising content, including comedy clips, movie, TV series, sports, local attractions, reality shows, commentaries, and documentaries. In addition, the company develops and operates outdoor advertising platforms in gas stations, such as LED screens, billboards, and light boxes. Further, it operates CIBN-AirNet channel to broadcast network TV programs to air travelers. The company was formerly known as AirMedia Group Inc. AirNet Technology Inc. was founded in 2005 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with AirNet Technology falling 9.21% to $1.03 on Thursday while NASDAQ rose 0.81% to $13,926.05.

Earnings Per Share

As for profitability, AirNet Technology has a trailing twelve months EPS of $-1.74.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -557.18%.

More news about AirNet Technology.

6. Adial Pharmaceuticals (ADIL) – -8.07%

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

NASDAQ ended the session with Adial Pharmaceuticals dropping 8.07% to $2.96 on Thursday while NASDAQ jumped 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Adial Pharmaceuticals has a trailing twelve months EPS of $-9.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -191.26%.

Yearly Top and Bottom Value

Adial Pharmaceuticals’s stock is valued at $2.96 at 17:32 EST, way under its 52-week high of $15.00 and higher than its 52-week low of $2.91.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 62.3% and 59.3%, respectively.

More news about Adial Pharmaceuticals.

7. Aethlon Medical (AEMD) – -8%

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

NASDAQ ended the session with Aethlon Medical falling 8% to $0.25 on Thursday while NASDAQ rose 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Aethlon Medical has a trailing twelve months EPS of $-0.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -88.52%.

Yearly Top and Bottom Value

Aethlon Medical’s stock is valued at $0.25 at 17:32 EST, way under its 52-week high of $1.00 and above its 52-week low of $0.23.

More news about Aethlon Medical.

8. Alnylam Pharmaceuticals (ALNY) – -7.14%

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Alnylam Pharmaceuticals dropping 7.14% to $196.53 on Thursday while NASDAQ jumped 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Alnylam Pharmaceuticals has a trailing twelve months EPS of $-8.97.

Sales Growth

Alnylam Pharmaceuticals’s sales growth is 36.7% for the present quarter and 21.3% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Alnylam Pharmaceuticals’s EBITDA is 21.37.

More news about Alnylam Pharmaceuticals.

9. Adverum Biotechnologies (ADVM) – -6.75%

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

NASDAQ ended the session with Adverum Biotechnologies dropping 6.75% to $1.52 on Thursday while NASDAQ jumped 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Adverum Biotechnologies has a trailing twelve months EPS of $-1.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.11%.

Yearly Top and Bottom Value

Adverum Biotechnologies’s stock is valued at $1.52 at 17:32 EST, way under its 52-week high of $2.34 and way above its 52-week low of $0.53.

More news about Adverum Biotechnologies.

10. Aesthetic Medical International Holdings Group Ltd. (AIH) – -6.61%

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 28 treatment centers in China, Hong Kong, and Singapore. The company was founded in 1997 and is headquartered in Shenzhen, China.

NASDAQ ended the session with Aesthetic Medical International Holdings Group Ltd. dropping 6.61% to $0.78 on Thursday while NASDAQ rose 0.81% to $13,926.05.

Earnings Per Share

As for profitability, Aesthetic Medical International Holdings Group Ltd. has a trailing twelve months EPS of $-0.39.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Aesthetic Medical International Holdings Group Ltd.’s EBITDA is 0.11.

Yearly Top and Bottom Value

Aesthetic Medical International Holdings Group Ltd.’s stock is valued at $0.78 at 17:32 EST, way below its 52-week high of $1.91 and way above its 52-week low of $0.61.

More news about Aesthetic Medical International Holdings Group Ltd..

Stay up to date with our winners and losers daily report